Diamyd Medical (Sweden) Performance
| DMYD-B Stock | SEK 17.18 0.08 0.47% |
On a scale of 0 to 100, Diamyd Medical holds a performance score of 12. The firm shows a Beta (market volatility) of -0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Diamyd Medical are expected to decrease at a much lower rate. During the bear market, Diamyd Medical is likely to outperform the market. Please check Diamyd Medical's market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to make a quick decision on whether Diamyd Medical's price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Diamyd Medical AB are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Diamyd Medical sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 139.4 M | |
| Total Cashflows From Investing Activities | -76.7 M |
Diamyd |
Diamyd Medical Relative Risk vs. Return Landscape
If you would invest 1,306 in Diamyd Medical AB on November 2, 2024 and sell it today you would earn a total of 412.00 from holding Diamyd Medical AB or generate 31.55% return on investment over 90 days. Diamyd Medical AB is generating 0.5179% of daily returns and assumes 3.265% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Diamyd, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Diamyd Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diamyd Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diamyd Medical AB, and traders can use it to determine the average amount a Diamyd Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1586
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DMYD-B | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.27 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.52 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Diamyd Medical is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diamyd Medical by adding it to a well-diversified portfolio.
Diamyd Medical Fundamentals Growth
Diamyd Stock prices reflect investors' perceptions of the future prospects and financial health of Diamyd Medical, and Diamyd Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diamyd Stock performance.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (170.83) % | |||
| Current Valuation | 1.06 B | |||
| Shares Outstanding | 76.93 M | |||
| Price To Earning | (4.21) X | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 2,531 X | |||
| Revenue | 454 K | |||
| EBITDA | (98.88 M) | |||
| Cash And Equivalents | 119.76 M | |||
| Cash Per Share | 1.02 X | |||
| Book Value Per Share | 2.36 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (1.45) X | |||
| Total Asset | 236.52 M | |||
| Retained Earnings | (31 M) | |||
| Current Asset | 33 M | |||
| Current Liabilities | 5 M | |||
About Diamyd Medical Performance
By analyzing Diamyd Medical's fundamental ratios, stakeholders can gain valuable insights into Diamyd Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Diamyd Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diamyd Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. Diamyd Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.Things to note about Diamyd Medical AB performance evaluation
Checking the ongoing alerts about Diamyd Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diamyd Medical AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diamyd Medical AB appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 454 K. Net Loss for the year was (118.18 M) with loss before overhead, payroll, taxes, and interest of (3.95 M). | |
| Diamyd Medical AB has accumulated about 119.76 M in cash with (93.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Diamyd Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diamyd Medical's stock is overvalued or undervalued compared to its peers.
- Examining Diamyd Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diamyd Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diamyd Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diamyd Medical's stock. These opinions can provide insight into Diamyd Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Diamyd Stock analysis
When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |